NUTRA PHARMA CORP
NPHC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NPHC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NPHC
Nutra Pharma Corp (NPHC) is a development-stage biotechnology company focused on drug development for multiple sclerosis and pain management, currently operating with minimal revenue and significant going-concern risks.
Key risk: Going concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$716K
Cash Runway
—
Lead Asset
nyloxin (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 2 clinical trials for NUTRA PHARMA CORP.
Nutra Pharma Corp (NPHC) is a development-stage biotechnology company focused on drug development for multiple sclerosis and pain management, currently operating with minimal revenue and significant going-concern risks.
- Received FDA Orphan Drug designation for lead candidate RPI-78M for Pediatric Multiple Sclerosis [sec_mda · as of 2026-05-20].
- As of December 31, 2025, the company had only $12,181 in cash and a working capital deficit of $16,813,637 [sec_mda · as of 2026-05-20].
- Total revenue was $0.0M and net income was -$3.9M for the latest reported period as of 2026-06-30 [sec].
- The company's common stock is traded on the OTC Market Group's Expert Market, limiting liquidity [sec_mda · as of 2026-03-11].
- Operations are funded through convertible notes and promissory notes, with $1,051,805 raised from convertible notes in 2025 [sec_mda · as of 2026-05-20].
What works
- FDA Orphan Drug designation for RPI-78M may shorten clinical timelines and allow Fast Track approval [sec_mda · as of 2026-05-20].
- The company has existing commercial products (Nyloxin and Pet Pain-Away) generating some revenue, though insufficient to cover costs [sec_mda · as of 2026-05-20].
- Management is actively seeking additional financing and has raised over $1 million in convertible notes in 2025 [sec_mda · as of 2026-05-20].
What to weigh
- The company has a substantial working capital deficit of $16.8 million and only $12,181 in cash as of December 31, 2025 [sec_mda · as of 2026-05-20].
- There is substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2026-03-11].
- The stock is on the OTC Expert Market, which restricts broker-dealer quotes and reduces investor access [sec_mda · as of 2026-03-11].
- The company relies heavily on related-party loans from its former CEO, with $1.34 million outstanding as of December 31, 2025 [sec_mda · as of 2026-05-20].
From the filings
Quoted directly from source documents.
FDA Orphan Drug designation for RPI-78M
“In September 2015, we received Orphan designation from the FDA for our lead drug candidate, RPI-78M for the treatment of Pediatric Multiple Sclerosis.”
SEC MD&A · May 20, 2026
Cash position and working capital deficit
“As of December 31, 2025, we had $12,181 in cash and owed approximately $5.10 million in vendor payables and accrued expenses.”
SEC MD&A · May 20, 2026
Going concern uncertainty
“As of the date of the filing of this report, we do not believe that our source of cash is adequate for the next 12 months of operation and there is substantial doubt about our ability to continue as a going concern.”
SEC MD&A · March 11, 2026
Stock traded on OTC Expert Market
“our common stock is presently on the OTC Market Group's Expert Market, which means that the Company's common stock is not eligible for proprietary broker-deal quotes.”
SEC MD&A · March 11, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Company has minimal cash and substantial doubt about ability to continue operations [sec_mda · as of 2026-03-11].
- Liquidity and trading risk — Stock on OTC Expert Market limits broker-deal quotes and investor access [sec_mda · as of 2026-03-11].
- Dependence on related-party loans — Relies on loans from former CEO; $1.34 million outstanding as of Dec 31, 2025 [sec_mda · as of 2026-05-20].
- Clinical development uncertainty — Pre-IND meeting for RPI-78M not yet completed; no guarantee of trial approval or funding [sec_mda · as of 2026-05-20].
What to watch
- Ability to secure additional financing or increase product sales to fund operations [sec_mda · as of 2026-05-20].
- Progress of pre-IND meeting with FDA for RPI-78M and potential start of Phase I/II trial [sec_mda · as of 2026-05-20].
- Changes in cash position and working capital in future filings [sec_mda · as of 2026-05-20].
- Any updates on stock trading status or potential uplisting from OTC Expert Market [sec_mda · as of 2026-03-11].
Sources: SEC MD&A · Generated August 23, 2026 · How we verify sources →
Run NUTRA PHARMA CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NUTRA PHARMA CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
OCF -$251K · Net income -$4M
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for NUTRA PHARMA CORP?
Nutra Pharma Corp (NPHC) is a development-stage biotechnology company focused on drug development for multiple sclerosis and pain management, currently operating with minimal revenue and significant going-concern risks.
What is NUTRA PHARMA CORP's lead drug candidate?
NUTRA PHARMA CORP's most advanced tracked candidate is nyloxin (Approved) for Moderate to severe chronic pain.
Who is the CEO of NUTRA PHARMA CORP?
Dr. Michael D. Flax D.D.S., M.S., P.A. is the chief executive officer of NUTRA PHARMA CORP (NPHC).
Where is NUTRA PHARMA CORP headquartered?
NUTRA PHARMA CORP (NPHC) is headquartered in Boca Raton, FL, United States.
What therapeutic areas does NUTRA PHARMA CORP focus on?
NUTRA PHARMA CORP develops therapies across Neurology, Immunology, Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.